Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100707 50 µg 30€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100708 200 µg 86€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  2. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  3. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  4. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  5. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  6. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  7. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  8. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  9. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  10. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  11. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  12. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  13. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  14. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  15. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  16. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  17. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  18. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  19. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  20. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  21. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  22. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  23. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  24. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  25. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  26. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  27. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  28. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  29. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  30. Diao L, et al. 2022. iScience. 25:105511. PubMed
  31. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  32. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  33. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  34. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  35. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  36. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  37. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  38. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  39. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  40. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  41. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  42. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  43. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  44. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  45. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  46. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  47. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  48. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  49. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  50. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  51. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  52. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  53. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  54. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  55. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  56. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  57. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  58. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  59. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  60. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  61. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  62. Li J, et al. 2019. JCI Insight. 5. PubMed
  63. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  64. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  65. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  66. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  67. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  68. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  69. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  70. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  71. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  72. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  73. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  74. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  75. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  76. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  77. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  78. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  79. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  80. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  81. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  82. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  83. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  84. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  85. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  86. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  87. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  88. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  89. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  90. Yang H, et al. 2022. Nutrients. 14:. PubMed
  91. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  92. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  93. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  94. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  95. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  96. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  97. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  98. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  99. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  100. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  101. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  102. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  103. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  104. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  105. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  106. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  107. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  108. Cho K, et al. 2021. iScience. 24:103117. PubMed
  109. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  110. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  111. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  112. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  113. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  114. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  115. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  116. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  117. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  118. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  119. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  120. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  121. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  122. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  123. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  124. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  125. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  126. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  127. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  128. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  129. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  130. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  131. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  132. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  133. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  134. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  135. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  136. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  137. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  138. Zhang J, et al. 2018. Nature. 553:91. PubMed
  139. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  140. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  141. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  142. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  143. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  144. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  145. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  146. Li J, et al. 2020. Development. :. PubMed
  147. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  148. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  149. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  150. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  151. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  152. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  153. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  154. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  155. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  156. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  157. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  158. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  159. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  160. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  161. Koide S, et al. 2022. iScience. 25:103603. PubMed
  162. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  163. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  164. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  165. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  166. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  167. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  168. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  169. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  170. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  171. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  172. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  173. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  174. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  175. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  176. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  177. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  178. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  179. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  180. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  181. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  182. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  183. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  184. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  185. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  186. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  187. Chavez JS, et al. 2022. Cells. 11:. PubMed
  188. Wang X, et al. 2022. Elife. 11:. PubMed
  189. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  190. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  191. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  192. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  193. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  194. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  195. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  196. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  197. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  198. Gawish R, et al. 2022. Elife. 11:. PubMed
  199. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  200. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  201. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  202. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  203. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  204. Zeng A, et al. 2020. Oncol Rep. . PubMed
  205. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  206. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
  207. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  208. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  209. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  210. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  211. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  212. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
RRID
AB_312746 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account